AI Jobs in Clinical Trials: In-Demand Roles and Salaries Across Europe

The AstraZeneca–insitro partnership, Isomorphic Labs' expanding deals with Novartis, Lilly, and J&J, and the EU AI Act's evolving requirements have done something that internal AI strategy decks alone rarely achieve: they have made AI in clinical development a board-level priority with a hiring budget attached.

Isomorphic Labs' collaborations with Novartis, Eli Lilly, and Johnson & Johnson are focused on AI-enabled drug discovery, but they illustrate the pipeline now forming between computational discovery and clinical validation. Eighteen months ago, most clinical operations functions did not have a dedicated AI role on their org chart. In 2026, they are building them quickly, and the talent to fill them is in short supply. This piece maps the ten roles at the centre of that shift, what they actually do, and what they pay across the European markets where hiring is most concentrated.

AI's earlier use cases in life sciences concentrated in drug discovery: target identification, generative chemistry, protein structure prediction. Those applications remain active, but the commercial pressure on clinical development is now at least as intense, and arguably more visible to sponsors and regulators.
 
The reasons are structural. Clinical development is typically among the largest and most expensive stages of bringing a drug to market. AI that can improve patient recruitment, optimise adaptive trial designs, generate and validate biomarkers, or accelerate data review has a direct and measurable effect on development timelines and costs. When Isomorphic Labs signs a collaboration with a major pharma company, the expectation is that the AI output eventually has to be tested in patients. The clinical development function is where that transition happens.
 
The EU AI Act has added a regulatory dimension driving hiring in its own right. The Act takes a risk-based approach: most AI systems face minimal or no additional obligations, while systems classified as high risk face requirements including risk management, data governance, logging, documentation, human oversight, and robustness measures. Transparency obligations under Article 50 began applying on 2 August 2026, while obligations for high-risk AI systems in certain sensitive areas apply from 2 December 2027. Whether a clinical-trial AI tool falls into a higher-risk category depends on its intended purpose, deployment context, and classification under the Act, not simply on the fact that it is used in a trial.
 
The compliance infrastructure those requirements demand is not theoretical. It needs people to build and maintain it.

Clinical AI Specialist

What they do: The Clinical AI Specialist is one of the roles most directly shaped by the EU AI Act's arrival in clinical development. They validate AI systems used within trials, maintain risk and evidence documentation, support conformity readiness where applicable, and work alongside regulatory affairs, clinical operations, and quality teams to ensure AI tools meet explainability and human oversight expectations. These professionals need enough technical literacy to interrogate a model and enough regulatory grounding to translate what they find into submission-ready documentation.

Where they sit: At pharma sponsors, CROs, and health AI companies building AI-enabled trial workflows.

AI Clinical Data Scientist

What they do: Develops and applies machine learning models to clinical datasets (EHR data, sensor data, imaging, lab values) to surface signals that standard statistical approaches miss. Works with biostatisticians and clinical operations teams to translate model outputs into decisions a trial can act on.

Where they sit: Primarily at mid-to-large pharma sponsors and clinical-stage biotechs with complex data environments.

Biostatistician with AI/ML Expertise

What they do: The evolution of a traditional biostatistics role. These professionals apply Bayesian methods, adaptive trial design, and machine learning-augmented analysis to clinical data while maintaining the statistical rigour that regulators require. They are not data scientists who have read a statistics textbook: they typically hold a PhD in biostatistics or a related discipline, with additional experience in computational methods.

Where they sit: At pharma and biotech sponsors, CROs, and academic medical centres with clinical research functions.

Clinical Trials Data Manager (AI)

What they do: Manages the data infrastructure underlying AI-enabled clinical trials: data governance, cleaning, integration across sources, and traceability requirements demanded by the EU AI Act and GCP guidelines. Increasingly responsible for assessing the quality and fitness-for-purpose of synthetic data where it supports trial planning, feasibility, or analysis.

Where they sit: At CROs, sponsors, and health data organisations.

Patient Recruitment AI Specialist

What they do: Applies predictive modelling and natural language processing to patient identification and recruitment, connecting EHR and real-world data to trial eligibility criteria to reduce the screening failure rates that slow enrolment and inflate costs. This role does not exist in most organisations yet. Demand is emerging from sponsors exploring whether AI-driven recruitment can improve identification, screening efficiency, and enrolment timelines, particularly in complex therapeutic areas such as oncology.

Where they sit: Mostly at large pharma sponsors and specialist clinical technology companies.

Decentralised Clinical Trial (DCT) Data Scientist

What they do: Decentralised and hybrid trials generate wearable sensor data, remote monitoring outputs, and patient-reported outcomes at a volume that traditional data management cannot handle. These data scientists build the pipelines and models that make that data usable, and work with clinical teams to validate what the signals mean.

Where they sit: Sponsors with active DCT programmes, clinical technology platforms.

AI Biomarker Scientist

What they do: Uses computational methods to identify, develop, and validate biomarkers for patient selection, dose optimisation, and outcome measurement across clinical development. The connection between AI-generated target hypotheses and the clinical trial that tests them runs through biomarker science, making this one of the highest-leverage roles in the AI-to-clinic pipeline.

Where they sit: Translational medicine and clinical pharmacology functions at pharma and biotech sponsors.

Regulatory AI Affairs Specialist

What they do: Navigates the intersection of AI Act compliance, EMA guidance on AI in the medicine lifecycle, and submission-ready documentation. These professionals advise on how AI tools used in development programmes should be characterised in regulatory filings, what documentation the EMA and national authorities will expect, and how to structure a risk management approach for AI systems used in a clinical or regulatory context. EMA's reflection paper sets out current thinking on AI across the medicinal product lifecycle, including patient selection, trial data recording, and analyses submitted for marketing authorisation.

Where they sit: Regulatory affairs functions at pharma sponsors and specialist regulatory consultancies.

Clinical ML Engineer

What they do: Builds, deploys, and maintains the machine learning infrastructure supporting clinical AI applications: model pipelines, integrations with clinical data systems, monitoring, and the MLOps practices that ensure models continue to perform reliably in a regulated clinical environment. The life sciences context adds validation, data-integrity, and documentation requirements that most ML engineers from outside the sector have not encountered.

Where they sit: Sponsors with internal AI platforms, clinical technology companies.

Head of AI for Clinical Development

What they do: Sets the strategy for how AI is adopted and governed across a clinical development function. Owns the relationship between AI capability and regulatory risk, oversees the AI validation programme, and leads the cross-functional teams (clinical operations, data management, biostatistics, regulatory affairs) that make AI-enabled trials work. These roles are beginning to emerge at director and VP level at large pharma sponsors.

Where they sit: Large pharma and biotech sponsors.

Compensation varies significantly by seniority, country, employer type, and whether the role is permanent or contract. The figures below are directional market estimates for 2026 across the Netherlands, Germany, Switzerland, and the UK. Actual packages vary by company stage, funding, equity, bonus, location, and seniority; treat them as planning benchmarks rather than definitive salary surveys.

Mid-level roles (Clinical AI Specialist, AI Clinical Data Scientist, DCT Data Scientist, Clinical Trials Data Manager)

• Permanent: €75,000–€110,000 base across NL/DE; CHF 130,000–170,000 in Switzerland
• Contract: €600–€850 per day

Senior roles (Biostatistician with AI/ML, AI Biomarker Scientist, Regulatory AI Affairs Specialist, Clinical ML Engineer)

• Permanent: €100,000–€160,000 base across NL/DE; CHF 170,000–220,000 in Switzerland
• Contract: €800–€1,100 per day

Lead and Director roles (Head of AI for Clinical Development, Principal AI Clinical Data Scientist)

• Permanent: €165,000–€240,000 base in Germany; CHF 215,000–275,000 in Switzerland; €135,000–€190,000 in the Netherlands
• Contract: €1,100–€1,600 per day for senior regulatory and AI governance expertise

Roles combining clinical domain expertise with strong AI governance or regulatory knowledge command a premium at all levels, reflecting the genuine scarcity of that combination in the European market. This is consistent with broader market evidence that senior AI and data roles in European life sciences increasingly command premium compensation, particularly in Switzerland and other major Western European hubs.

The Netherlands hosts a dense cluster of CROs, health data companies, and life-sciences organisations drawn to the EMA's presence in Amsterdam. Demand for clinical data management, regulatory AI affairs, and clinical AI governance roles is concentrated here.

Switzerland remains the highest-compensating market in European life sciences, with Roche, Novartis, and their networks driving demand for senior AI clinical development profiles in Basel and Zurich. Contract rates for senior AI roles in Switzerland are at or near European peaks.

Germany combines large pharma presence (Bayer, Boehringer Ingelheim, Merck KGaA) with a growing CRO sector and an active decentralised trial ecosystem. Munich and Berlin are both active hiring markets for clinical data science and ML engineering roles.

The UK, despite operating outside EU regulatory frameworks, remains a significant market for clinical AI hiring through AstraZeneca (Cambridge), GSK (London), and a dense concentration of AI-native biotech and clinical technology companies. Isomorphic Labs, Exscientia, and BenevolentAI are all UK-headquartered. AI Act compliance requirements apply to clinical work conducted within the EU, keeping regulatory AI affairs active as a specialism for UK-based professionals working on EU programmes.

Do I need a clinical background to move into AI roles in clinical trials?

Domain knowledge matters significantly. Roles like Biostatistician with AI/ML, AI Biomarker Scientist, and Clinical AI Specialist require a foundation in clinical, statistical, or regulatory science that cannot be substituted with computational skill alone. For roles like Clinical ML Engineer or DCT Data Scientist, strong technical credentials can be supplemented by gaining GCP exposure through the role.

Are these roles predominantly permanent or contract?

Both markets are active. Mid-level clinical data management and data science roles lean toward permanent. Senior AI governance, regulatory AI affairs, and interim clinical AI leadership are actively contracted, particularly as companies build compliance programmes ahead of EU AI Act high-risk obligations arriving in December 2027.

Which qualifications are most useful for clinical AI roles?

Biostatisticians typically hold a PhD in biostatistics or a related discipline. Clinical AI Specialists and Regulatory AI Affairs professionals increasingly benefit from familiarity with the EU AI Act, EMA's reflection paper on AI in the medicinal product lifecycle, ICH E6/GCP expectations, data-integrity principles, and relevant CDISC standards. ML Engineers benefit from demonstrating GxP, computerised-system validation, and data-integrity experience alongside standard MLOps qualifications.

Panda recruits across data science, bioinformatics, AI engineering, and clinical AI for life sciences organisations across Europe. If you are building an AI-enabled clinical development team, talk to our team.